Leukemia inhibitory factor suppresses hepatic de novo lipogenesis and induces cachexia in mice
-
Published:2024-01-20
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Yang Xue, Wang JianmingORCID, Chang Chun-YuanORCID, Zhou Fan, Liu Juan, Xu Huiting, Ibrahim Maria, Gomez Maria, Guo Grace L., Liu Hao, Zong Wei-Xing, Wondisford Fredric E., Su XiaoyangORCID, White EileenORCID, Feng ZhaohuiORCID, Hu WenweiORCID
Abstract
AbstractCancer cachexia is a systemic metabolic syndrome characterized by involuntary weight loss, and muscle and adipose tissue wasting. Mechanisms underlying cachexia remain poorly understood. Leukemia inhibitory factor (LIF), a multi-functional cytokine, has been suggested as a cachexia-inducing factor. In a transgenic mouse model with conditional LIF expression, systemic elevation of LIF induces cachexia. LIF overexpression decreases de novo lipogenesis and disrupts lipid homeostasis in the liver. Liver-specific LIF receptor knockout attenuates LIF-induced cachexia, suggesting that LIF-induced functional changes in the liver contribute to cachexia. Mechanistically, LIF overexpression activates STAT3 to downregulate PPARα, a master regulator of lipid metabolism, leading to the downregulation of a group of PPARα target genes involved in lipogenesis and decreased lipogenesis in the liver. Activating PPARα by fenofibrate, a PPARα agonist, restores lipid homeostasis in the liver and inhibits LIF-induced cachexia. These results provide valuable insights into cachexia, which may help develop strategies to treat cancer cachexia.
Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference64 articles.
1. Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C. & Fearon, K. C. H. Cancer-associated cachexia. Nat. Rev. Dis. Primers 4, 17105 (2018). 2. Ferrer, M. et al. Cachexia: a systemic consequence of progressive, unresolved disease. Cell 186, 1824–1845 (2023). 3. Pryce, B. R., Wang, D. J., Zimmers, T. A., Ostrowski, M. C. & Guttridge, D. C. Cancer cachexia: involvement of an expanding macroenvironment. Cancer Cell 41, 581–584 (2023). 4. Rohm, M., Zeigerer, A., Machado, J. & Herzig, S. Energy metabolism in cachexia. EMBO Rep. 20, e47258 (2019). 5. Biswas, A. K. & Acharyya, S. Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer 20, 274–284 (2020).
|
|